



INDO-BANGLA PHARMACEUTICALS LIMITED

PLOT # 183 (7th FLOOR), BLOCK # B, AHMED AKBER SOBHAN ROAD,
BASHUNDHARA R/A, Dhaka-1229.

PRICE SENSITIVE INFORMATION

This is for kind information that, the Board of Directors of Indo-Bangla Pharmaceuticals Limited (“Company”) in its meeting held on **Tuesday 30th January, 2024 at 4:00 p.m.** at the corporate office, has approved the Un-Audited Financial Statements for the Second Quarter (Q2) period ended on 31th December, 2023.

The key financial highlights for the Second Quarter ended 31th December, 2023 are appended below:

Particulars	As at 31.12.2023	As at 30.06.2023
Net Asset Value (NAV) Per Share	Tk. 13.91	Tk. 13.96

Particulars	July to December 2023	July to December 2022	October to December 2023	October to December 2022
Earnings Per Share (EPS)	Tk. (0.05)	Tk. 0.09	Tk. (0.06)	Tk. (0.08)
Net Operating Cash Flow Per Share (NOCFPS)	Tk. 0.23	Tk. 0.05	–	–

The reasons, for significant deviation:

- **Earnings Per Share (EPS)** has been decreased compared to the same period of the previous year due to decreased in sales revenue and also increased cost of revenue due to disruption in supply chain for crisis of US dollar, limitation for opening L/C to import raw materials, Russia & Ukraine War and price hike of Electricity.
- **NOCFPS** has been increased due to decrease in supplier's payment during the reporting period.
- **NAVPS** has also been decreased due to net loss after tax.

By order of the Board of Directors

-sd-

(Mohi Uddin QCS)

Company Secretary

The details of the published Second Quarter (Q2) Financial Statements are available in the website of the company: www.indo-banglapharma.com.